Emcure Pharmaceuticals Ltd. (EMCURE) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹2,215 (-2.85% day change)
Key ratios
- P/E ratio
- 45.42
- P/B ratio
- 6.11
- ROE (%)
- 18.67
- ROCE (%)
- 24.1
- Debt/Equity
- 0.31
- Dividend yield (%)
- 0.19
- Market cap (₹ Cr)
- 41,294.54
Forensic checks
Piotroski F-Score: 5/9 · Altman Z-Score: 7.73 · Beneish M-Score: -2.32
InvestSights quality score
74.1/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- R&D spend as % of revenue: guided 4–5%, delivered 4.5% (FY25) — met guidance
- Revenue growth: guided 13–14%, delivered 17.87% (FY26) — exceeded guidance
Latest earnings call (Q2 FY27)
AI summary: The central signal was the upgrade in FY27 revenue-growth guidance to exceed 20%, backed by multiple businesses rather than a single product. International revenue grew 34.5% to ₹1,665 crores, with Europe, Canada and RoW all expanding, while management confirmed that liposomal amphotericin B remained below 10% of international sales. This reduces the immediate concern that…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.